Celgene Corp (CELG) Stock Price Declined While Bridgewater Associates LP Has Increased by $21.37 Million Its Position

April 23, 2018 - By Hazel Jackson

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.83 in Q4 2017. Its down 0.34, from 1.17 in 2017Q3. It fall, as 156 investors sold CELG shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported. Beacon Inc holds 1.28% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 1,146 shares. Washington holds 0.79% or 135,085 shares in its portfolio. Thrivent For Lutherans stated it has 1.64M shares. Stock Yards Bank Tru Company reported 147,819 shares. Tci Wealth Advisors reported 2,031 shares. Braun Stacey Associates reported 0.53% stake. Matarin Mgmt Lc invested in 0.22% or 26,628 shares. Goldman Sachs Grp Inc invested 0.21% of its portfolio in Celgene Corporation (NASDAQ:CELG). Moreover, Highbridge Cap Limited Liability has 0.23% invested in Celgene Corporation (NASDAQ:CELG). Qci Asset Mgmt New York owns 42 shares or 0% of their US portfolio. Adams Asset Limited invested 0.11% of its portfolio in Celgene Corporation (NASDAQ:CELG). Smithfield Tru has 0.02% invested in Celgene Corporation (NASDAQ:CELG) for 1,471 shares. Bermuda-based Fil Ltd has invested 0.19% in Celgene Corporation (NASDAQ:CELG). Lmr Ptnrs Ltd Liability Partnership stated it has 0.1% of its portfolio in Celgene Corporation (NASDAQ:CELG). Seatown Pte accumulated 303,398 shares or 2.99% of the stock.

Since February 8, 2018, it had 1 buying transaction, and 3 sales for $3.58 million activity. $1.77M worth of Celgene Corporation (NASDAQ:CELG) was sold by KAPLAN GILLA. Another trade for 13,370 shares valued at $1.26 million was sold by MARIO ERNEST. 3,260 shares were bought by Alles Mark J, worth $299,594.

Ray Dalio increased its stake in Celgene Corp (CELG) by 240.94% based on its latest 2017Q4 regulatory filing with the SEC. Bridgewater Associates Lp bought 205,490 shares as the company’s stock declined 19.30% with the market. The hedge fund run by Ray Dalio held 290,776 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $30.35M, up from 85,286 at the end of the previous reported quarter. Bridgewater Associates Lp who had been investing in Celgene Corp for a number of months, seems to be bullish on the $66.91B market cap company. The stock decreased 0.75% or $0.67 during the last trading session, reaching $88.95. About 6.23 million shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since April 23, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Bridgewater Associates Lp, which manages about $12.21B US Long portfolio, decreased its stake in Bce Inc (NYSE:BCE) by 72,660 shares to 84,392 shares, valued at $4.07M in 2017Q4, according to the filing. It also reduced its holding in Devon Energy Corp New (NYSE:DVN) by 332,411 shares in the quarter, leaving it with 218,491 shares, and cut its stake in Juniper Networks Inc (NYSE:JNPR).

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 27 analysts covering Celgene (NASDAQ:CELG), 15 have Buy rating, 1 Sell and 11 Hold. Therefore 56% are positive. Celgene has $166 highest and $91.0 lowest target. $123.45’s average target is 38.79% above currents $88.95 stock price. Celgene had 46 analyst reports since October 26, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, October 26 by Cowen & Co. Canaccord Genuity maintained Celgene Corporation (NASDAQ:CELG) on Friday, October 27 with “Buy” rating. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, April 13 report. The firm earned “Outperform” rating on Wednesday, February 28 by BMO Capital Markets. The stock has “Buy” rating by BMO Capital Markets on Monday, January 8. The rating was maintained by SunTrust with “Buy” on Thursday, January 25. SunTrust maintained the shares of CELG in report on Friday, December 22 with “Buy” rating. The rating was maintained by Stifel Nicolaus on Monday, January 8 with “Buy”. The firm has “Buy” rating by Guggenheim given on Thursday, December 21. Citigroup maintained Celgene Corporation (NASDAQ:CELG) on Friday, October 27 with “Neutral” rating.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.